News | March 08, 2007

Many Drug-Eluting Stent Procedures Not Approved by FDA

March 9, 2007 — New studies show that about 60 percent of drug-eluting stents are used in off-label indications in the U.S. A series of studies is published in the March 8 issue of the New England Journal of Medicine.

Release of these studies comes on the heels of of a U.S. House committee request March 5 for safety data from two key manufacturers of coated stents. Rep. Henry Waxman, D.-CA., chairman of the House Oversight and Government Reform Committee, asked Boston Scientific and Johnson & Johnson to provide documents on their stents as part of an investigation into product safety and off-label use, according to news reports.

Jeff Mirviss, vice president of stent marketing at Boston Scientific told “Diagnostic & Invasive Cardiology” Thursday that his company approaches FDA and the public with complete transparency regarding its DFUs and the specifics of its FDA-cleared stent indications. Both Boston Scientific and the FDA, he said, want to preserve the individual choices of physicians, who use DES at their case-by-case discretion to treat patients with blocked coronary arteries.

The coated stents have FDA approval for use in patients with a single blocked artery who do not have any accompanying medical problems, such as diabetes. But the journal studies indicate that many patients are getting several stents, some under emergency conditions, such as following a heart attack, even when there are other medical complications, according to a HealthDay Reporter article.

The FDA meeting was held because of reports that patients receiving coated stents had a higher rate of blood clots. But that problem was "a small concern" compared to widespread off-label use, said Dr. Andrew Farb, an FDA medical officer who wrote an accompanying perspective piece in the journal.

Medicare is reviewing whether it will continue to pay for off-label use of the coated stents, according to Dr. Gregory D. Curfman, executive editor of the journal. "We have no idea what Medicare will do," he said. "Obviously, it would be a major step if they did not reimburse for off-label use."

The newer studies are aimed at heightening awareness of the issue, Dr. Farb said. "When you have any type of medical intervention, when you see more complicated patients or lesions, you will see a higher rate of adverse events," he said. "That is what has been observed in these studies. Our goal is to make the medical community at large aware of the issue."

In part because of such findings, "the percentage of drug-eluting stents that are being implanted has declined over the past few months," said Dr. William Maisel, a cardiologist at Beth Israel Deaconess Medical Center in Boston, who wrote another perspective piece for the journal.

Studies are needed to answer questions about off-label use, says Dr. William Maisel, a cardiologist at Beth Israel Deaconess Medical Center in Boston, who wrote another perspective piece for the journal.

"Data currently are not sufficient to make a decision," he said. "It is important to make a distinction between something you know to be bad and something you don't know the answer to, and to many off-label uses we don't know the answer," he said.

Another pressing issue is that of late thrombosis, or blood clots, in stent recipients, both Maisel and Farb said. Studies show a slight but definite increase of these clots, generally linked to discontinuation of the anti-clotting medications Plavix and aspirin.

According to Mirviss at Boston Scientific, overall occurrence of late stent thrombosis is one to two percent.
The widespread off-label use of drug-coated stents "is an enormous public health concern" he added. "It is extremely important for patients and the medical society to understand this issue."

One major problem is that cardiologists often use stents in cases where "the recommended gold standard therapy is coronary bypass surgery," Michler said.

This article includes original reporting by Ed Edelson, HealthDay Reporter.

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init